VSTM · XBRL financial data

Verastem financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VSTM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	2	3	—	10	31
Revenue from contracts with customers	89	2	3	—	10	—
Research and development	41	39	51	61	81	115
Selling, general and administrative	63	24	25	31	44	81
Operating income (loss)	(49)	(61)	(73)	(92)	(115)	(170)
Interest income	1	0	1	6	4	4
Interest expense	16	10	2	4	5	1
Other income (expense)	(1)	—	0	(0)	(0)	(0)
Income tax expense (benefit)	0	0	0	—	0	—
Net income (loss)	(68)	(71)	(74)	(87)	(131)	(209)
Earnings per share, basic USD per share	(0.44)	(0.41)	(0.38)	(3.96)	(3.66)	(3.02)
Earnings per share, diluted USD per share	(0.44)	(0.41)	(0.38)	(3.93)	(3.66)	(3.02)
Weighted average shares, basic millions of shares	153	174	194	22	36	69
Weighted average shares, diluted millions of shares	153	174	0	22	36	69

† Share count changed about 1/8 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (VSTM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	68	21	75	78	89	205
Marketable securities	73	79	13	59	—	—
Inventory	—	—	—	—	—	2
Prepaid and other current assets	3	5	5	7	6	8
Total current assets	145	106	93	144	95	223
Property and equipment, net	0	0	0	0	0	—
Right-of-use asset	3	2	2	1	1	0
Total assets	154	109	95	150	102	246
Accounts payable	2	2	5	7	4	12
Accrued liabilities	15	16	15	18	26	54
Total current liabilities	17	19	22	26	31	72
Lease liability, non-current	3	2	1	1	1	—
Total liabilities	39	21	48	71	130	189
Accumulated deficit	(593)	(664)	(738)	(825)	(956)	(1,165)
Total stockholders' equity	115	88	47	57	(29)	57
Total liabilities and equity	154	109	95	150	102	246
Common shares outstanding (cover page) millions of shares	172	186	201	25	25	88

† Share count changed about 1/8 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (VSTM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(68)	(71)	(74)	(87)	(131)	(209)
Stock-based compensation	8	8	6	6	7	9
Net cash from operating activities	(34)	(54)	(64)	(86)	(105)	(138)
Purchases of property and equipment	0	0	—	—	0	—
Net cash from investing activities	(47)	0	66	(44)	60	(10)
Proceeds from issuing common stock	106	7	27	91	14	197
Repayments of long-term debt	37	—	—	0	—	43
Net cash from financing activities	70	7	52	134	55	263
Net change in cash	(11)	(47)	54	3	10	116

† Share count changed about 1/8 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Verastem	136	40	(44)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Corvus Pharmaceuticals	19	not reported	(15)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	166	1.6	(52)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Atea Pharmaceuticals	77	not reported	(37)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199	not reported	(48)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	62	70	(28)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Tonix Pharmaceuticals Holding	176	14	(42)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Abeona Therapeutics	56	11	(17)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	21	not reported	(2.2)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.